EP3738599A4 - Composition comprenant des probiotiques et un polypeptide présentant une affinité de liaison pour les ige et son utilisation - Google Patents
Composition comprenant des probiotiques et un polypeptide présentant une affinité de liaison pour les ige et son utilisation Download PDFInfo
- Publication number
- EP3738599A4 EP3738599A4 EP19738433.2A EP19738433A EP3738599A4 EP 3738599 A4 EP3738599 A4 EP 3738599A4 EP 19738433 A EP19738433 A EP 19738433A EP 3738599 A4 EP3738599 A4 EP 3738599A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- probiotics
- ige
- polypeptide
- composition
- binding affinity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 title 1
- 239000006041 probiotic Substances 0.000 title 1
- 235000018291 probiotics Nutrition 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20180004421 | 2018-01-12 | ||
PCT/KR2019/000524 WO2019139434A1 (fr) | 2018-01-12 | 2019-01-14 | Composition comprenant des probiotiques et un polypeptide présentant une affinité de liaison pour les ige et son utilisation |
Publications (4)
Publication Number | Publication Date |
---|---|
EP3738599A1 EP3738599A1 (fr) | 2020-11-18 |
EP3738599A4 true EP3738599A4 (fr) | 2021-10-27 |
EP3738599C0 EP3738599C0 (fr) | 2023-12-27 |
EP3738599B1 EP3738599B1 (fr) | 2023-12-27 |
Family
ID=67218660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19738433.2A Active EP3738599B1 (fr) | 2018-01-12 | 2019-01-14 | Composition comprenant des probiotiques et un polypeptide présentant une affinité de liaison pour les ige et son utilisation |
Country Status (17)
Country | Link |
---|---|
US (1) | US20220347236A1 (fr) |
EP (1) | EP3738599B1 (fr) |
JP (1) | JP7041272B2 (fr) |
KR (1) | KR102038679B1 (fr) |
CN (1) | CN111587118B (fr) |
AU (1) | AU2019206205A1 (fr) |
BR (1) | BR112020013818A2 (fr) |
CA (1) | CA3086224A1 (fr) |
CL (1) | CL2020001800A1 (fr) |
ES (1) | ES2969110T3 (fr) |
IL (1) | IL275593B (fr) |
MX (1) | MX2020007032A (fr) |
PE (1) | PE20210108A1 (fr) |
PH (1) | PH12020551069A1 (fr) |
SG (1) | SG11202005863TA (fr) |
TW (1) | TWI737955B (fr) |
WO (1) | WO2019139434A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2022000285A (es) * | 2019-07-08 | 2022-02-03 | Gi Innovation Inc | Dimero de polipeptido con alto contenido de acido sialico, que comprende el dominio extracelular de la subunidad alfa del receptor fc de ige y composicion farmaceutica que comprende el mismo. |
US20230279124A1 (en) * | 2020-07-17 | 2023-09-07 | Gi Innovation, Inc. | Fusion protein comprising ige fc receptor alpha subunit extracellular domain and anti-il-4r antibody, and use thereof |
KR20220011931A (ko) * | 2020-07-22 | 2022-02-03 | (주)지아이이노베이션 | IgE Fc 수용체를 포함하는 융합단백질 및 이를 포함하는 개 알레르기성 질환 치료 용도 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008028068A2 (fr) * | 2006-08-30 | 2008-03-06 | Genentech, Inc. | POLYPEPTIDES FCεR1α DE PRIMATES NON HUMAINS |
WO2019135668A1 (fr) * | 2018-01-08 | 2019-07-11 | 주식회사 프로젠 | Domaine extracellulaire de sous-unité alpha du récepteur fc ige, composition pharmaceutique le comprenant et son procédé de production |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH092959A (ja) * | 1995-06-16 | 1997-01-07 | Yakult Honsha Co Ltd | IgE抗体産生抑制剤および抗アレルギー剤 |
JPH10309178A (ja) * | 1997-05-09 | 1998-11-24 | Wakamoto Pharmaceut Co Ltd | ビフィズス菌を有効成分とする抗アレルギー剤および醗酵食品 |
JP2000095697A (ja) * | 1998-09-18 | 2000-04-04 | Advance Co Ltd | 抗アレルギー剤 |
AUPQ415899A0 (en) * | 1999-11-19 | 1999-12-16 | Vasse Research Institute Pty Ltd | Compositions for and methods of treatment of allergic diseases |
EP1239032A1 (fr) * | 2001-03-02 | 2002-09-11 | Société des Produits Nestlé S.A. | Bactéries lactiques en tant qu'agents pour le traitement et la prévention des allergies |
JP2009067679A (ja) * | 2005-12-27 | 2009-04-02 | Univ Of Tokushima | 抗ヒスタミン作用を有する医薬 |
US20100303777A1 (en) * | 2006-12-14 | 2010-12-02 | Actogenix N.V. | Delivery of binding molecules to induce immunomodulation |
AR065368A1 (es) * | 2007-02-15 | 2009-06-03 | Astrazeneca Ab | Anticuerpos para moleculas de ige |
ES2623925T3 (es) | 2007-05-30 | 2017-07-12 | Postech Academy-Industry- Foundation | Proteínas de fusión de inmunoglobulina |
EP2065048A1 (fr) * | 2007-11-30 | 2009-06-03 | Institut Pasteur | Utilisation d'une souche de L. casei pour la préparation d'une composition pour l'inhibition de l'activation de mastocytes |
CA2713525A1 (fr) * | 2008-02-06 | 2009-08-13 | The Procter & Gamble Company | Compositions, methodes et kits de stimulation de la reponse immunitaire a une maladie respiratoire |
WO2010013143A2 (fr) * | 2008-08-01 | 2010-02-04 | Institut Pasteur | Procédés d'inhibition de l'activation des mastocytes et de traitement de maladies et de troubles inflammatoires dépendant des mastocytes, faisant appel à lactobacillus |
ES2742419T3 (es) | 2008-09-17 | 2020-02-14 | Xencor Inc | Nuevas composiciones y métodos para tratar trastornos mediados por IgE |
BR112012009846B8 (pt) * | 2009-10-26 | 2021-05-25 | Genentech Inc | método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige |
KR20120135865A (ko) * | 2011-06-07 | 2012-12-17 | (주)네오팜 | FcεRI의 수용성 단편을 포함하는 복합체 및 이를 포함하는 IgE 매개 알레르기성 질환 치료용 조성물 |
WO2012169735A2 (fr) * | 2011-06-07 | 2012-12-13 | (주)네오팜 | Complexe comprenant des fragments hydrosolubles de fcεri et composition le contenant pour traiter les maladies allergiques médiées par l'ige |
CN103169733B (zh) * | 2011-12-26 | 2014-11-12 | 浙江贝因美科工贸股份有限公司 | 复合益生菌、其在治疗过敏性疾病中的应用及孕产妇防过敏益生菌冲剂 |
TWI691512B (zh) * | 2015-02-20 | 2020-04-21 | 日商橘生藥品工業股份有限公司 | Fc融合高親和性IgE受體α鏈 |
JP2018515426A (ja) * | 2015-03-12 | 2018-06-14 | ザ ユニヴァーシティ オブ ブリティッシュ コロンビア | 細菌組成物およびその使用方法 |
KR101778734B1 (ko) | 2016-03-11 | 2017-09-18 | 대한민국(농촌진흥청장) | 비피도박테리움 롱검 kacc 91563으로부터 분리된 esbp 및 이를 이용한 항알레르기 조성물 |
-
2019
- 2019-01-14 PE PE2020000943A patent/PE20210108A1/es unknown
- 2019-01-14 MX MX2020007032A patent/MX2020007032A/es unknown
- 2019-01-14 EP EP19738433.2A patent/EP3738599B1/fr active Active
- 2019-01-14 WO PCT/KR2019/000524 patent/WO2019139434A1/fr unknown
- 2019-01-14 US US16/959,016 patent/US20220347236A1/en active Pending
- 2019-01-14 KR KR1020190004610A patent/KR102038679B1/ko active IP Right Grant
- 2019-01-14 SG SG11202005863TA patent/SG11202005863TA/en unknown
- 2019-01-14 CA CA3086224A patent/CA3086224A1/fr active Pending
- 2019-01-14 AU AU2019206205A patent/AU2019206205A1/en active Pending
- 2019-01-14 BR BR112020013818-5A patent/BR112020013818A2/pt unknown
- 2019-01-14 ES ES19738433T patent/ES2969110T3/es active Active
- 2019-01-14 JP JP2020537681A patent/JP7041272B2/ja active Active
- 2019-01-14 TW TW108101372A patent/TWI737955B/zh active
- 2019-01-14 CN CN201980008124.5A patent/CN111587118B/zh active Active
-
2020
- 2020-06-22 IL IL275593A patent/IL275593B/en unknown
- 2020-07-03 CL CL2020001800A patent/CL2020001800A1/es unknown
- 2020-07-10 PH PH12020551069A patent/PH12020551069A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008028068A2 (fr) * | 2006-08-30 | 2008-03-06 | Genentech, Inc. | POLYPEPTIDES FCεR1α DE PRIMATES NON HUMAINS |
WO2019135668A1 (fr) * | 2018-01-08 | 2019-07-11 | 주식회사 프로젠 | Domaine extracellulaire de sous-unité alpha du récepteur fc ige, composition pharmaceutique le comprenant et son procédé de production |
Non-Patent Citations (1)
Title |
---|
See also references of WO2019139434A1 * |
Also Published As
Publication number | Publication date |
---|---|
ES2969110T3 (es) | 2024-05-16 |
TW201932129A (zh) | 2019-08-16 |
JP2021510689A (ja) | 2021-04-30 |
AU2019206205A1 (en) | 2020-06-25 |
CN111587118B (zh) | 2023-11-21 |
EP3738599C0 (fr) | 2023-12-27 |
WO2019139434A1 (fr) | 2019-07-18 |
IL275593B (en) | 2022-01-01 |
SG11202005863TA (en) | 2020-07-29 |
EP3738599B1 (fr) | 2023-12-27 |
TWI737955B (zh) | 2021-09-01 |
IL275593A (en) | 2020-08-31 |
CN111587118A (zh) | 2020-08-25 |
CA3086224A1 (fr) | 2019-07-18 |
EP3738599A1 (fr) | 2020-11-18 |
BR112020013818A2 (pt) | 2020-12-01 |
CL2020001800A1 (es) | 2020-10-30 |
PE20210108A1 (es) | 2021-01-19 |
RU2020122021A (ru) | 2022-02-14 |
KR20190086396A (ko) | 2019-07-22 |
JP7041272B2 (ja) | 2022-03-23 |
MX2020007032A (es) | 2020-12-03 |
KR102038679B1 (ko) | 2019-10-30 |
PH12020551069A1 (en) | 2021-09-06 |
US20220347236A1 (en) | 2022-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3856787A4 (fr) | PROTÉINES DE LIAISON SIRPalpha ET MÉTHODES D'UTILISATION DE CELLES-CI | |
EP3652212A4 (fr) | Anticorps de liaison à lag-3 et leurs utilisations | |
EP3612218A4 (fr) | Protéines de liaison à un antigène anti-trem2 et leurs utilisations | |
EP3635013A4 (fr) | Protéines de liaison à la nectine-4 et leurs procédés d'utilisation | |
EP3810172A4 (fr) | Protéines hétérodimères et utilisations associées | |
EP3927740A4 (fr) | Anticorps se liant à l'albumine et leurs utilisation | |
IL275593B (en) | A preparation containing probiotics and peptides with binding affinity to ige and its uses | |
EP3613771A4 (fr) | Molécule de liaison spécifique à protéine lrig-1 et son utilisation | |
EP3802617A4 (fr) | Protéines de liaison multi-spécifiques et procédés d'utilisation associés | |
EP3718540A4 (fr) | Protéine de fusion comprenant une glutathion-s-transférase et une protéine ayant une affinité de liaison pour une cellule cible ou une protéine cible, et utilisation correspondante | |
IL284381A (en) | Anti-4 CTLA binding proteins from activatable screens, compositions containing them and uses thereof | |
EP3763800A4 (fr) | Composition de matériau de stockage de froid et son utilisation | |
EP3445394A4 (fr) | Protéines de liaison à alk7 et leurs utilisations | |
EP3705121A4 (fr) | Agent de liaison à une protéine de liaison à l'émopamil et son utilisation | |
EP4013789A4 (fr) | Anticorps se liant à vista et leurs utilisations | |
EP3805386A4 (fr) | Protéine cas9 modifiée et utilisation de celle-ci | |
EP3813861A4 (fr) | Polypeptides associés à l'héparine et leurs utilisations | |
EP3816186A4 (fr) | Polypeptide se liant au pd-l1 et son utilisation | |
EP3700571A4 (fr) | Protéines de liaison à alk7 et leurs utilisations | |
EP3802831A4 (fr) | Polypeptide comprenant un domaine de liaison de il-1r1 et une fraction de transport | |
EP4004021A4 (fr) | Polypeptides ayant des effets anti-sénescence et leurs utilisations | |
EP3976656A4 (fr) | Protéines de liaison à alk7 et leurs utilisations | |
EP4077385A4 (fr) | Protéines de liaison à cxcl10 et leurs utilisations | |
EP4023663A4 (fr) | Polypeptide et son utilisation | |
EP4013785A4 (fr) | Protéines de liaison au complément c2 et leurs utilisations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200629 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20210927 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 37/08 20060101ALI20210921BHEP Ipc: A61K 9/00 20060101ALI20210921BHEP Ipc: A61K 9/14 20060101ALI20210921BHEP Ipc: A61K 35/747 20150101ALI20210921BHEP Ipc: A61K 35/745 20150101ALI20210921BHEP Ipc: A61K 39/395 20060101ALI20210921BHEP Ipc: A61K 35/744 20150101AFI20210921BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20220921 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/42 20060101ALI20230502BHEP Ipc: C07K 14/705 20060101ALI20230502BHEP Ipc: A61K 9/19 20060101ALI20230502BHEP Ipc: A61P 37/08 20060101ALI20230502BHEP Ipc: A61K 9/00 20060101ALI20230502BHEP Ipc: A61K 9/14 20060101ALI20230502BHEP Ipc: A61K 35/747 20150101ALI20230502BHEP Ipc: A61K 35/745 20150101ALI20230502BHEP Ipc: A61K 39/395 20060101ALI20230502BHEP Ipc: A61K 35/744 20150101AFI20230502BHEP |
|
INTG | Intention to grant announced |
Effective date: 20230606 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTC | Intention to grant announced (deleted) | ||
INTG | Intention to grant announced |
Effective date: 20230906 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602019044019 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
U01 | Request for unitary effect filed |
Effective date: 20240122 |
|
U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI Effective date: 20240131 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240328 |
|
U20 | Renewal fee paid [unitary effect] |
Year of fee payment: 6 Effective date: 20240306 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240328 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20240318 Year of fee payment: 6 Ref country code: GB Payment date: 20240229 Year of fee payment: 6 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2969110 Country of ref document: ES Kind code of ref document: T3 Effective date: 20240516 |